Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd

Link copied
Case Copied 21 min read

FEDERAL COURT OF AUSTRALIA

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2015] FCA 848

Citation: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2015] FCA 848
Appeal from: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634
Parties: OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY v GENERIC HEALTH PTY LTD (ACN 110 617 859) and COMMONWEALTH OF AUSTRALIA
File number: NSD 837 of 2015
Judge: NICHOLAS J
Date of judgment: 14 August 2015
Catchwords:

PRACTICE AND PROCEDURE – where appellants seek stay of primary judge’s order vacating interlocutory injunction granted to appellants in proceeding for patent infringement – where relevant claims of patent held invalid – principles governing application for stay pending appeal – consideration of strength of appeal and balance of convenience – relevant considerations where respondent is supplier of generic pharmaceutical product seeking to list its products on Pharmaceutical Benefits Scheme (“PBS”)

PRACTICE AND PROCEDURE – whether Commonwealth of Australia should have benefit of an undertaking as to damages that is specific to it – whether appellants should be required to provide security in relation to any claim by the Commonwealth on the appellants’ undertaking as to damages notwithstanding that the Commonwealth is not a party and the interlocutory injunction in question is not directed to the Commonwealth

Held: stay granted and orders made requiring appellants to provide security to the respondent and the Commonwealth in respect of any entitlement to compensation payable under the usual undertaking as to damages

Legislation: Federal Court of Australia Act 1976 (Cth) ss 25(2B), 25(6)
Federal Court Rules 2011 (Cth)
Federal Court Rules 1979 (Cth)
Therapeutic Goods Act 1989 (Cth) Ch 3, Pt 3-2, Div 2
Cases cited: Powerflex Services Pty Ltd v Data Access Corp (1996) 67 FCR 65
Seven Network (Operations) Limited v Endemol Australia Pty Limited [2015] FCA 800
Date of hearing: 13 August 2015
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 47
Counsel for the Appellants: Mr AJL Bannon SC with Ms CL Cochrane
Solicitor for the Appellants: Allens
Counsel for the Respondent: Mr A Ryan SC
Solicitor for the Respondent: Bird & Bird
Counsel for the Commonwealth of Australia: Mr T Howe QC with Mr PM Knowles
Solicitor for the Commonwealth of Australia: Corrs Chambers Westgarth
Table of Corrections

19 August 2015

In paragraph 20, “s 26(2B)(ab)” has been replaced with “s 25(2B)(ab)”
11 September 2015 In paragraph 5, second sentence, the words “Generic Health does oppose” amended to read “Generic Health does not oppose”

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 837 of 2015

ON APPEAL FROM THE FEDERAL COURT OF AUSTRALIA
BETWEEN:

OTSUKA PHARMACEUTICAL CO., LTD
First Appellant

BRISTOL-MYERS SQUIBB COMPANY
Second Appellant

AND:

GENERIC HEALTH PTY LTD (ACN 110 617 859)
Respondent

AND: COMMONWEALTH OF AUSTRALIA
Other

JUDGE:

NICHOLAS J

DATE OF ORDER:

14 AUGUST 2015

WHERE MADE:

SYDNEY

THE COURT NOTES THAT:

1.The appellants, by their solicitor, Philip John Kerr, undertake to the Court:

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] FCA 848
Decision Date

CaseChat Overview and Summary

In the case of Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd, the primary dispute arose from an interlocutory injunction granted by the primary judge to the appellants in a proceeding for patent infringement. The primary judge vacated this injunction upon finding that the relevant claims of the patent were invalid. The appellants sought a stay of the primary judge's order pending the determination of their appeal. The court had to decide whether to grant a stay and the appropriate terms for such a stay, including whether the Commonwealth should receive an undertaking as to damages specific to it and whether the appellants should provide security in relation to any claim by the Commonwealth.

The court considered the principles governing the application for a stay pending appeal, focusing on the strength of the appeal and the balance of convenience. The court found that the appeal had a reasonable prospect of success given the issues of patent validity. Additionally, the balance of convenience favoured the appellants, considering the respondent's intention to list generic products on the Pharmaceutical Benefits Scheme, which could significantly affect the market and the appellants' business. The court held that the Commonwealth, though not a party, should benefit from an undertaking as to damages specific to it, and that the appellants should provide security for such undertakings.

The court granted the stay and made several orders. The operation of certain orders made by Justice Yates was stayed until the appeal was determined. The respondent was required to withdraw any application it had made to list its products under the Pharmaceutical Benefits Scheme by a specified date. The appellants were ordered to provide additional security to the respondent and the Commonwealth in specified amounts by a set date. The court also prohibited the publication or disclosure of certain confidential annexures to affidavits filed in the appeal proceedings. Each party, including the Commonwealth, was granted liberty to apply for further orders. The costs of the interlocutory applications were reserved.

Orders

Orders of the court

1. The operation of orders 1, 2, 4 and 7 made by Justice Yates on 16 July 2015 in Federal Court Proceeding No. NSD 121 of 2012 be stayed until the determination of these appeal proceedings or further order.

2. By no later than 5pm on 16 September 2015, the respondent withdraw any application it has made to obtain listing under the Pharmaceutical Benefits Scheme maintained by the Commonwealth of Australia (“Commonwealth”) under the National Health Act 1953 (Cth) of any of the GH products (as that term is defined in the reasons for judgment delivered by Justice Yates on 29 June 2015 in Federal Court Proceeding No NSD 121 of 2012).

3. The first appellant provide additional security in favour of the respondent for:

(a) the appellants’ undertaking as to damages provided to Justice Yates on 22 March 2012;

(b) the undertakings set out in paragraph 1(a) and 1(b) above; and

(c) the respondent’s costs of the proceeding before Yates J and the appeal

in the amount of $8.7 million by no later than 14 September 2015, such security to be provided in the form of an unconditional and irrevocable bank guarantee issued by an Australian trading bank in favour of the respondent and served on the respondent no later than 14 September 2015.

4. The first appellant provide security in favour of the Commonwealth for the undertakings set out in paragraph 1(a) and 1(b) above in the amount of $6.0 million by no later than 14 September 2015, such security to be provided in the form of an unconditional and irrevocable bank guarantee issued by an Australian trading bank in favour of the Commonwealth and served on the Commonwealth no later than 14 September 2015.

5. Until further order, publication or disclosure of Confidential Annexures “MK-3”, “MK-4”, “MK-6” and “MK-8” to the affidavit of Masamitsu Kitada, affirmed on 17 July 2015 and filed in these appeal proceedings, is prohibited (the Court being satisfied that such order is necessary to prevent prejudice to the proper administration of justice).

6. Until further order, publication or disclosure of Confidential Annexures “MRM-3”, “MRM-4”, “MRM-5” and “MRM-9” to the affidavit of Mohammed Raza Merchant, sworn on 30 July 2015 and filed in these appeal proceedings, is prohibited (the Court being satisfied that such order is necessary to prevent prejudice to the proper administration of justice).

7. Each of the parties (which for this purpose includes the Commonwealth) has liberty to apply on 3 days’ notice in relation to these orders.

8. Costs of the interlocutory applications be reserved.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.